Westway Health (WWH) is a biopharmaceutical company based in Galway, on the west coast of Ireland. After being approached by Killian and Brian O'Briain of Mayo Healthcare, a leading Irish animal nutrition company, almost a decade ago, research into this topic began in the laboratory of Prof Vincent O’Flaherty in the department of microbiology at National University of Ireland, Galway. Prof O’Flaherty and Dr Paul Mc Cay, in an attempt to address the growing problem of antimicrobial resistance, developed a range of non-antibiotic antimicrobial technologies. These technologies are effective against all microorganisms tested, including antibiotic-resistant organisms, such as MRSA. Additionally due to the mechanism of action of these technologies, microorganisms are highly unlikely to develop a resistance to the WWH technologies – delivering safe, effective solutions for the future. Westway Health is developing its novel antimicrobial technologies in a range of applications in the fields of human health, animal health and environmental sterilisation. Prof O'Flaherty and WWH CEO, Dr. Ruairi Friel, lead the research team in bringing the novel PanaMast product to commercialisation, under the H2020 SME Phase 2 instrument.